China's SAMR weighs generic-drug entry as potential competition in merger reviews
Expected entry of generic drugs following the expiry of patent exclusivity may provide an effective competitive constraint in Chinese merger reviews, according to analysis of three cases published by China’s State...To view the full article, register now.
Already a subscriber? Click here to view full article